Fucose Supplementation for Glut1 Deficiency Syndrome

CB
Overseen ByCelena Byerlee-Dixon
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of L-fucose supplementation in subjects with GLUT1 deficiency syndrome (GLUT1DS).

Who Is on the Research Team?

RT

Rodrigo T. Starosta, MD, PhD

Principal Investigator

Oregon Health and Science University

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 years old or older.
I have GLUT1DS confirmed by genetic test, low CSF glucose, or typical symptoms.
I have problems with coordination or balance (ataxia).

Exclusion Criteria

I am unable to swallow liquids.
I have changed my neurological medications or dosages in the last 90 days.
Use of fucose- or mannose-containing supplements within one year of enrollment
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive L-fucose or placebo for 12 weeks, followed by a cross-over to the alternate treatment for another 12 weeks

24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • L-fucose

How Is the Trial Designed?

2

Treatment groups

Active Control

Placebo Group

Group I: L-fucose followed by placeboActive Control2 Interventions
Group II: Placebo followed by L-fucosePlacebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Oregon Health and Science University

Lead Sponsor

Trials
1,024
Recruited
7,420,000+

Glut1 Deficiency Foundation

Collaborator